P379: PONATINIB AND BLINATUMOMAB IN RELAPSED/REFRACTORY PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE: SUBGROUP ANALYSIS FROM A PHASE II TRIAL

P379: PONATINIB AND BLINATUMOMAB IN RELAPSED/REFRACTORY PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE: SUBGROUP ANALYSIS FROM A PHASE II TRIAL

Bibliographic Details
Main Authors:	Fadi Haddad, Elias Jabbour, Marianne Zoghbi, Nicholas Short, Cedric Nasnas, Lewis Nasr, Walid Macaron, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Tapan Kadia, Naval Daver, Kelly Chien, Yesid Alvarado, Guillermo Garcia-Manero, Ghayas Issa, Monica Kwari, Ricardo Delumpa, Ejiroghene Mayor, Wuliamatu Deen, Jennifer Thankachan, Christopher Loiselle, Juan Rivera, Anna Milton, Lourdes Waller, Glenda Banks, Rebecca Garris, Farhad Ravandi, Hagop Kantarjian
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000968428.69134.08

Similar Items

P364: A PHASE II STUDY OF LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
by: Fadi Haddad, et al.
Published: (2023-08-01)

S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY
by: Nicholas Short, et al.
Published: (2023-08-01)

S114: PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY
by: N. Short, et al.
Published: (2022-06-01)

P373: UPDATES FROM A PHASE II TRIAL OF MINI-HYPER-CVD-INOTUZUMAB WITH OR WITHOUT BLINATUMOMAB IN OLDER PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA
by: Fadi Haddad, et al.
Published: (2023-08-01)

P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY
by: Nicholas Short, et al.
Published: (2023-08-01)

S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL
by: Fadi Haddad, et al.
Published: (2023-08-01)

P371: HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
by: N. Short, et al.
Published: (2022-06-01)

P355: MINI-HYPER-CVD PLUS INOTUZUMAB OZOGAMICIN, WITH OR WITHOUT BLINATUMOMAB, IN OLDER ADULTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATES FROM A PHASE II TRIAL
by: F. Haddad, et al.
Published: (2022-06-01)

P485: AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY
by: Nicholas Short, et al.
Published: (2023-08-01)

P377: A PHASE II TRIAL OF MINI-HYPER-CVD WITH VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
by: Fadi Haddad, et al.
Published: (2023-08-01)

P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB
by: W. Macaron, et al.
Published: (2022-06-01)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
by: Hagop Kantarjian, et al.
Published: (2023-05-01)

Acute myeloid leukemia: current progress and future directions
by: Hagop Kantarjian, et al.
Published: (2021-02-01)

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
by: Aram Bidikian, et al.
Published: (2022-10-01)

P369: A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA
by: J. Senapati, et al.
Published: (2022-06-01)

Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab
by: Hagop M. Kantarjian, et al.
Published: (2023-10-01)

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
by: Hagop M. Kantarjian, et al.
Published: (2021-11-01)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
by: Nicholas J. Short, et al.
Published: (2019-02-01)

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
by: Fausto Castagnetti, et al.
Published: (2021-03-01)

Ponatinib in chronic myeloid leukemia: Finally getting it right?
by: Bhausaheb Bagal, et al.
Published: (2020-01-01)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
by: Alex Bataller, et al.
Published: (2023-08-01)

P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA
by: Martin C. Müller, et al.
Published: (2023-08-01)

PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT
by: Serap Karaman, et al.
Published: (2021-11-01)

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
by: Robert Briski, et al.
Published: (2023-10-01)

P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS
by: J. Apperley, et al.
Published: (2022-06-01)

Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
by: Max S. Topp, et al.
Published: (2021-04-01)

Probable ponatinib-induced papilledema in a patient with acute lymphocytic leukemia
by: Jared A. Moon, et al.
Published: (2023-12-01)

Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia
by: Francesca Musumeci, et al.
Published: (2018-11-01)

Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia
by: Michele Basile, et al.
Published: (2021-07-01)

BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia
by: Narissa Parry, et al.
Published: (2022-11-01)

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
by: Lee KJ, et al.
Published: (2016-08-01)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
by: Le Jeune C, et al.
Published: (2016-02-01)

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
by: Kamal Chamoun, et al.
Published: (2019-01-01)

Immunotherapy in Acute Myeloid Leukemia: Where We Stand
by: Alessandro Isidori, et al.
Published: (2021-05-01)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
by: Claudio Cerchione, et al.
Published: (2021-03-01)

Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
by: Kazuki Tanimura, et al.
Published: (2021-02-01)

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study
by: Patrick K. Reville, et al.
Published: (2021-03-01)

P379: MUTATIONAL LANDSCAPE IN THERAPY-RELATED ACUTE LYMPHOBLASTIC LEUKEMIA
by: K. D. Hofer, et al.
Published: (2022-06-01)

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment
by: Hoda Pourhassan, et al.
Published: (2023-08-01)

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
by: Portell CA, et al.
Published: (2013-04-01)